Cwm LLC Sells 3,184 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

CWM LLC cut its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 65.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,707 shares of the biotechnology company's stock after selling 3,184 shares during the period. CWM LLC's holdings in United Therapeutics were worth $526,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in UTHR. Norges Bank acquired a new stake in shares of United Therapeutics during the fourth quarter valued at about $151,764,000. FMR LLC grew its holdings in shares of United Therapeutics by 36.5% in the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock valued at $519,170,000 after purchasing an additional 393,777 shares in the last quarter. Vaughan Nelson Investment Management L.P. acquired a new position in shares of United Therapeutics in the first quarter valued at approximately $101,354,000. GAMMA Investing LLC grew its holdings in shares of United Therapeutics by 29,415.2% in the first quarter. GAMMA Investing LLC now owns 221,954 shares of the biotechnology company's stock valued at $68,422,000 after purchasing an additional 221,202 shares in the last quarter. Finally, Alliancebernstein L.P. grew its holdings in shares of United Therapeutics by 28.5% in the fourth quarter. Alliancebernstein L.P. now owns 709,043 shares of the biotechnology company's stock valued at $250,179,000 after purchasing an additional 157,363 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Trading Down 0.6%

NASDAQ UTHR traded down $1.91 during trading hours on Friday, reaching $304.50. The company's stock had a trading volume of 310,921 shares, compared to its average volume of 372,488. The business has a 50-day simple moving average of $300.01 and a 200 day simple moving average of $315.85. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $417.82. The stock has a market cap of $13.74 billion, a PE ratio of 12.15, a PEG ratio of 6.64 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating the consensus estimate of $6.29 by $0.34. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The company had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. During the same quarter last year, the business earned $6.17 earnings per share. United Therapeutics's revenue was up 17.2% compared to the same quarter last year. As a group, equities analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insider Activity

In other United Therapeutics news, Director Nilda Mesa sold 645 shares of the firm's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total value of $187,043.55. Following the sale, the director owned 4,883 shares in the company, valued at approximately $1,416,021.17. This trade represents a 11.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $304.11, for a total transaction of $3,345,210.00. Following the completion of the sale, the executive vice president owned 36,781 shares in the company, valued at $11,185,469.91. The trade was a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 81,681 shares of company stock worth $24,628,589 over the last ninety days. 10.30% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. UBS Group reduced their price objective on shares of United Therapeutics from $410.00 to $385.00 and set a "buy" rating for the company in a research report on Monday, June 30th. Wells Fargo & Company restated an "equal weight" rating and set a $314.00 price objective (down previously from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Bank of America reduced their price target on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research report on Wednesday, June 11th. Wall Street Zen downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. Finally, Morgan Stanley reduced their price target on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research report on Thursday, July 10th. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $383.08.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.